Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma

计划入组 95 人 · 首次发布于 2022 年 3 月 31 日

Virus-specific Activated T Lymphocytes From a Donor in Hematopoietic Progenitor Transplanted Patients

计划入组 26 人 · 首次发布于 2019 年 7 月 12 日

Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)

计划入组 7 人 · 首次发布于 2014 年 1 月 30 日

LuLym-T

autologous activated T-lymphocytes

Activated T-lymphocytes (GC Pharma)

T-Knife GmbH

Germany

PH & T SpA

Italy

T-Balance Therapeutics GmbH

Germany

Immunotech-B Targets 39-Month Timeline for EAL Resubmission in Liver Cancer, Advances ATL Cell Therapy Commercialization

King Hussein Cancer Center Achieves Breakthrough with CAR-T Cell Therapy

Tumor-Infiltrating Lymphocytes Emerge as Key Biomarkers for NSCLC Immunotherapy Response